Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : UMDF
Deal Size : Undisclosed
Deal Type : Funding
UMDF Supports Khondrion Drug Development for Primary Mitochondrial Disease
Details : The proceeds will be used for the development of KH176 (sonlicromanol), a first-in-class, brain-penetrant redox-modulator, for adults with primary mitochondrial disease due to the m.3243A>G mutation.
Brand Name : KH176
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 21, 2024
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : UMDF
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Patients treated with KH176 (sonlicromanol) for 28 days did not achieve statistically significant improvement in attention domain score of cognitive functioning, as assessed by the computerised Cogstate visual identification test, compared to those who r...
Brand Name : KH176
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 22, 2022
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Topline data from KHENERGYZE Phase IIb trial for KH176 (sonlicromanol) is expected in the third quarter of 2022, Phase IIa study showed a significant improvement in attention and mood-related outcomes in patients with MELAS spectrum disorder.
Brand Name : KH176
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 10, 2022
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Khondrion Receives EMA Agreement on its Paediatric Investigation Plan for Sonlicromanol
Details : With the acceptance of the PIP, Khondrion plans to initiate a paediatric trial to evaluate the safety and efficacy of sonlicromanol in children from birth to less than 18 years with mitochondrial disease affecting oxidative phosphorylation and symptoms o...
Brand Name : KH176
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2021
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : An ongoing Phase 2B clinical trial in patients with MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) spectrum disorders is investigating the effect of sonlicromanol on cognitive functioning.
Brand Name : KH176
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 27, 2020
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sonlicromanol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company’s lead asset sonlicromanol may have potential as a repurposed treatment for PGE2-driven inflammatory consequences underlying severe COVID-19 disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 15, 2020
Lead Product(s) : Sonlicromanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study’s primary objective is to evaluate the dose-effect of Sonlicromanol on the attention domain score of cognitive functioning, Results are expected in the second half of 2020.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 27, 2020
Lead Product(s) : Sonlicromanol
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?